Health Canada approves Rhythm’s IMCIVREE for weight management
RYTM - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
Story updates
12:01:14 PM UTC
SquawkNews
RYTM - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
12:04:43 PM UTC
SquawkNews
Rhythm Pharmaceuticals received Health Canada approval for IMCIVREE for weight management in adults and children 4+ with acquired hypothalamic obesity, supported by a Phase 3 showing an 18.8% placebo—adjusted BMI reduction.Material DetailsContext by AI AnalystThis is a label expansion building on p…